Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Working Capital Changes (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Other Working Capital Changes for 14 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 251.18% year-over-year to $3.8 million, compared with a TTM value of -$438000.0 through Dec 2025, down 201.39%, and an annual FY2025 reading of -$438000.0, down 201.39% over the prior year.
  • Other Working Capital Changes was $3.8 million for Q4 2025 at Karyopharm Therapeutics, up from -$4.7 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $15.6 million in Q1 2022 and bottomed at -$10.3 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is -$355550.0, with a median of -$692500.0 recorded in 2023.
  • The sharpest move saw Other Working Capital Changes soared 5352.53% in 2022, then tumbled 2716.17% in 2025.
  • Year by year, Other Working Capital Changes stood at -$4.9 million in 2021, then plummeted by 109.89% to -$10.3 million in 2022, then surged by 126.62% to $2.7 million in 2023, then crashed by 191.28% to -$2.5 million in 2024, then skyrocketed by 251.18% to $3.8 million in 2025.
  • Business Quant data shows Other Working Capital Changes for KPTI at $3.8 million in Q4 2025, -$4.7 million in Q3 2025, and $2.4 million in Q2 2025.